5050 Nathan Lane
175 articles about Abbott
Late-Breaking Data Demonstrate Abbott's FreeStyle Libre® 3 System is Most Accurate 14-Day Continuous Glucose Monitor
Abbott announced late-breaking clinical data that demonstrate the FreeStyle Libre® 3 system has an overall mean absolute relative difference of 7.9%,1 making it the first and only 14-day continuous glucose monitoring system to achieve a sub-8% overall MARD.
Abbott Enters into Consent Decree with U.S. Food and Drug Administration for its Sturgis, Mich., Plant; Agreement Creates Pathway to Reopen Facility
Abbott has agreed to enter into a consent decree with the U.S. Food and Drug Administration related to its Sturgis, Mich., infant formula plant.
Abbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise
Abbott announced it has received FDA clearance for its Alinity™ m STI Assay.
Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2022.
Abbott Receives FDA Approval for Aveir™ VR Leadless Pacemaker System to Treat Patients with Slow Heart Rhythms
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Aveir™ single-chamber (VR) leadless pacemaker for the treatment of patients in the U.S. with slow heart rhythms.
Abbott's CardioMEMS™ HF System Receives FDA Approval to Support Patients Battling Earlier-Stage Heart Failure
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for the company's CardioMEMS™ HF System to support the care of more people living with heart failure.
The board of directors of Abbott declared a quarterly common dividend of 47 cents per share.
Abbott's investigational Aveir™ DR dual-chamber pacemaker is designed to provide synchronous, beat-by-beat pacing of the right atrium and right ventricle of the heart.
Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2021, and issued its financial outlook for 2022.
Abbott will announce its fourth-quarter 2021 financial results on Wednesday, Jan. 26, 2022, before the market opens.
Abbott will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 11, 2022. Robert B. Ford, chairman and chief executive officer, will present at 8 a.m. Central time.
Abbott announced that its Board of Directors has elected Chief Executive Officer Robert B. Ford as Chairman of the Board.
Abbott and the American Diabetes Association® Launch First-of-Its-Kind Community Initiative in Columbus, Ohio, to Advance Access to Diabetes Care and Technology
Abbott and the American Diabetes Association® announced the launch of their first joint community health partnership.
Abbott Receives FDA Clearance for its Imaging Technology Using Artificial Intelligence for Vessels in the Heart
Abbott today announced it has received U.S. Food and Drug Administration (FDA) clearance for its latest optical coherence tomography (OCT) imaging platform powered by the company's new Ultreon Software.
Abbott's FreeStyle® Libre 2 iOS App Cleared in U.S., Providing a Seamless Digital Experience to Simplify Diabetes Management
- FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone every minute with optional real-time glucose alarms
New Study: Half of Americans Living with Diabetes May be Consuming Less Than the Recommended Amount of Protein, which is Associated with Greater Physical Limitations
A new study conducted by The Ohio State University and Abbott showed that half of the adults surveyed living with diabetes did not consume the daily recommended intake of protein, which is associated with lower diet quality, increased carbohydrate intake, and greater physical limitations.
Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2021.
Abbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients
Abbott (NYSE: ABT) today announced its XIENCE family of stents has received U.S. Food and Drug Administration (FDA) approval for one-month (as short as 28 days) DAPT labeling for high bleeding risk (HBR) patients
- Abbott has the capacity and supply to support increased demand for mechanical circulatory support (MCS) devices following Medtronic's decision to stop the global distribution and sale of the Medtronic HeartWare™ ventricular assist device (HVAD) - Access to MCS devices are critical for advanced heart failure patients and can improve survival, clinical outcomes and quality of life
- Sales growth of 35.3 percent; organic sales growth of 32.9 percent - GAAP diluted EPS growth from continuing operations of 233.3 percent; adjusted diluted EPS growth of 103.1 percent - All four major businesses achieved strong sales growth in the quarter - Projected full-year EPS remains unchanged; reflects growth of more than 35 percent